Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
20.7M
Short interest
settlement 2026-10-15
11.2
Days to cover
-6.8 days vs prior
69.4%
Short share of volume
2026-11-02
3
Fails to deliver
settlement 2026-10-02
Thu 5 Nov
Next earnings
estimated date
-$137
Insider flow, 90 days
0 buys, 1 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in GLUE is 20,660,257 shares, up 1,394,267 shares over the last month. Over the last 48 readings it ranged from 5,414,033 shares (31 March 2025) to 20,660,257 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 1.8M shares a day that is 11.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/glue" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 20,660,257 | +5.0% | 1,837,865 | 11.24 |
| 2026-09-30 | 19,686,241 | +2.2% | 1,093,381 | 18.00 |
| 2026-09-15 | 19,265,990 | +6.6% | 1,127,772 | 17.08 |
| 2026-08-31 | 18,075,786 | +3.5% | 1,091,293 | 16.56 |
| 2026-08-14 | 17,457,317 | +6.1% | 1,247,991 | 13.99 |
| 2026-07-31 | 16,458,543 | -4.3% | 1,554,197 | 10.59 |
| 2026-07-15 | 17,195,471 | -7.7% | 1,314,790 | 13.08 |
| 2026-06-30 | 18,634,735 | +8.5% | 2,195,951 | 8.49 |
| 2026-06-15 | 17,170,729 | +7.3% | 1,033,043 | 16.62 |
| 2026-05-29 | 16,005,122 | +7.0% | 832,953 | 19.21 |
| 2026-05-15 | 14,962,299 | -1.2% | 725,334 | 20.63 |
| 2026-04-30 | 15,142,638 | -4.4% | 848,528 | 17.85 |
| 2026-04-15 | 15,837,633 | +18.2% | 990,243 | 15.99 |
| 2026-03-31 | 13,398,925 | +22.2% | 1,520,828 | 8.81 |
| 2026-03-13 | 10,964,393 | +8.4% | 867,615 | 12.64 |
| 2026-02-27 | 10,115,500 | +8.4% | 945,395 | 10.70 |
| 2026-02-13 | 9,330,612 | +21.8% | 1,005,178 | 9.28 |
| 2026-01-30 | 7,664,016 | +38.0% | 1,138,207 | 6.73 |
| 2026-01-15 | 5,554,802 | -34.3% | 4,043,321 | 1.37 |
| 2025-12-31 | 8,454,052 | +20.8% | 1,459,903 | 5.79 |
| 2025-12-15 | 7,001,428 | -0.1% | 739,854 | 9.46 |
| 2025-11-28 | 7,006,369 | -5.3% | 812,508 | 8.62 |
| 2025-11-14 | 7,396,896 | -7.4% | 1,087,763 | 6.80 |
| 2025-10-31 | 7,988,754 | -1.2% | 1,045,303 | 7.64 |
| 2025-10-15 | 8,082,854 | +3.2% | 1,355,619 | 5.96 |
| 2025-09-30 | 7,831,770 | -5.0% | 1,362,952 | 5.75 |
| 2025-09-15 | 8,239,631 | -0.0% | 3,435,778 | 2.40 |
| 2025-08-29 | 8,241,602 | -1.0% | 329,775 | 24.99 |
| 2025-08-15 | 8,321,153 | -4.4% | 410,919 | 20.25 |
| 2025-07-31 | 8,701,757 | -2.4% | 482,728 | 18.03 |
| 2025-07-15 | 8,919,776 | +0.7% | 376,500 | 23.69 |
| 2025-06-30 | 8,862,358 | -0.1% | 471,584 | 18.79 |
| 2025-06-13 | 8,872,105 | +9.9% | 443,486 | 20.01 |
| 2025-05-30 | 8,075,031 | -3.8% | 491,115 | 16.44 |
| 2025-05-15 | 8,395,716 | +6.6% | 361,835 | 23.20 |
| 2025-04-30 | 7,876,484 | +4.6% | 532,316 | 14.80 |
| 2025-04-15 | 7,532,066 | +39.1% | 1,082,912 | 6.96 |
| 2025-03-31 | 5,414,033 | -23.0% | 996,914 | 5.43 |
| 2025-03-14 | 7,033,824 | -12.5% | 629,113 | 11.18 |
| 2025-02-28 | 8,042,209 | +0.2% | 421,752 | 19.07 |
| 2025-02-14 | 8,029,011 | -0.6% | 374,506 | 21.44 |
| 2025-01-31 | 8,074,830 | -7.8% | 757,814 | 10.66 |
| 2025-01-15 | 8,755,986 | -4.3% | 1,175,120 | 7.45 |
| 2024-12-31 | 9,144,923 | +8.8% | 1,328,106 | 6.89 |
| 2024-12-13 | 8,404,331 | -24.0% | 2,277,630 | 3.69 |
| 2024-11-29 | 11,054,976 | -0.9% | 849,203 | 13.02 |
| 2024-11-15 | 11,152,201 | +42.3% | 1,285,572 | 8.67 |
| 2024-10-31 | 7,837,789 | +49.8% | 8,722,587 | 1.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of GLUE volume is 69.4%, up 31.1 points over the last five sessions. Over the last 30 readings it ranged from 17.8% (27 October 2026) to 79.5% (12 October 2026). The latest reading is 13.1 points above the 30-session average of 56.3%, on 476K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 331K | 476K | 69.4% | 0 |
| 2026-10-30 | 368K | 492K | 74.8% | 0 |
| 2026-10-29 | 297K | 500K | 59.4% | 0 |
| 2026-10-28 | 444K | 697K | 63.7% | 0 |
| 2026-10-27 | 105K | 586K | 17.8% | 0 |
| 2026-10-26 | 92K | 241K | 38.3% | 0 |
| 2026-10-23 | 121K | 238K | 51.1% | 0 |
| 2026-10-22 | 276K | 412K | 67.1% | 0 |
| 2026-10-21 | 153K | 334K | 45.8% | 0 |
| 2026-10-20 | 458K | 649K | 70.7% | 0 |
| 2026-10-19 | 468K | 730K | 64.0% | 0 |
| 2026-10-16 | 167K | 290K | 57.6% | 0 |
| 2026-10-15 | 312K | 416K | 75.0% | 204 |
| 2026-10-14 | 243K | 445K | 54.5% | 307 |
| 2026-10-13 | 566K | 1.2M | 47.8% | 0 |
| 2026-10-12 | 701K | 881K | 79.5% | 0 |
| 2026-10-09 | 346K | 475K | 72.9% | 0 |
| 2026-10-08 | 171K | 498K | 34.3% | 0 |
| 2026-10-07 | 448K | 659K | 68.0% | 1,400 |
| 2026-10-06 | 192K | 452K | 42.4% | 0 |
| 2026-10-05 | 357K | 661K | 54.0% | 2,900 |
| 2026-10-02 | 364K | 775K | 47.0% | 4,550 |
| 2026-10-01 | 721K | 1.1M | 65.2% | 900 |
| 2026-09-30 | 202K | 278K | 72.9% | 30 |
| 2026-09-29 | 76K | 159K | 47.6% | 0 |
| 2026-09-28 | 99K | 250K | 39.6% | 0 |
| 2026-09-25 | 137K | 305K | 45.1% | 0 |
| 2026-09-24 | 140K | 488K | 28.7% | 0 |
| 2026-09-23 | 208K | 358K | 58.2% | 0 |
| 2026-09-22 | 403K | 530K | 76.1% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 2 October 2026, the fails-to-deliver balance in GLUE is 3 shares, down 15 shares over the last settlement date. Over the last 30 readings it ranged from 3 shares (2 October 2026) to 408,788 shares (3 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-02 | 3 | $11.26 | $34 |
| 2026-09-23 | 18 | $12.60 | $227 |
| 2026-09-17 | 54,787 | $12.65 | $693K |
| 2026-09-15 | 8,665 | $13.90 | $120K |
| 2026-09-02 | 1,482 | $14.31 | $21K |
| 2026-08-03 | 408,788 | $16.52 | $6.8M |
| 2026-07-21 | 1,747 | $23.48 | $41K |
| 2026-07-17 | 922 | $23.16 | $21K |
| 2026-07-16 | 26 | $23.41 | $609 |
| 2026-07-15 | 2,805 | $23.46 | $66K |
| 2026-07-09 | 778 | $24.06 | $19K |
| 2026-07-08 | 1,827 | $24.40 | $45K |
| 2026-07-07 | 1,035 | $23.25 | $24K |
| 2026-07-06 | 1,863 | $24.21 | $45K |
| 2026-07-01 | 12,100 | $24.20 | $293K |
| 2026-06-30 | 100,592 | $23.90 | $2.4M |
| 2026-06-29 | 104,323 | $22.29 | $2.3M |
| 2026-06-24 | 13,276 | $20.71 | $275K |
| 2026-06-22 | 18,398 | $18.31 | $337K |
| 2026-06-18 | 35 | $18.41 | $644 |
| 2026-06-15 | 1,555 | $18.24 | $28K |
| 2026-06-08 | 180 | $16.37 | $3K |
| 2026-05-26 | 22 | $18.81 | $414 |
| 2026-05-22 | 263 | $18.88 | $5K |
| 2026-05-19 | 83 | $18.01 | $1K |
| 2026-05-08 | 17,415 | $19.81 | $345K |
| 2026-05-04 | 3,111 | $18.80 | $58K |
| 2026-04-20 | 6,718 | $19.78 | $133K |
| 2026-04-15 | 99 | $17.50 | $2K |
| 2026-04-13 | 4 | $17.48 | $70 |
Insider trades
SEC Form 4, newest first. JSONInsiders at GLUE reported 1 open-market sell worth $137 in the last 90 days and no open-market buys. Latest filing: Bowen Matthew (Principal Accounting Officer) on 2026-10-05.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Bowen Matthew | Principal Accounting Officer | Sell | 13 | $10.56 | $137 | 26K |
| 2026-07-16 | Warmuth Markus | President & CEO | Sell | 10K | $23.18 | $220K | 585K |
| 2026-07-15 | Champoux Jennifer | Chief Operating Officer | Sell | 4K | $23.38 | $102K | 62K |
| 2026-07-15 | Champoux Jennifer | Chief Operating Officer | Exercise or conversion | 4K | $3.98 | $17K | 67K |
| 2026-07-06 | Townson Sharon | Chief Scientific Officer | Sell | 400 | $24.13 | $10K | 68K |
| 2026-07-06 | Townson Sharon | Chief Scientific Officer | Sell | 6K | $23.25 | $130K | 68K |
| 2026-07-06 | Townson Sharon | Chief Scientific Officer | Exercise or conversion | 6K | $6.14 | $37K | 74K |
| 2026-07-01 | Behbahani Ali | Director | Other transaction | 15K | $0.00 | $0 | 0 |
| 2026-07-01 | Behbahani Ali | Director | Other transaction | 15K | $0.00 | $0 | 15K |
| 2026-07-01 | Behbahani Ali | Director | Other transaction | 1.0M | $0.00 | $0 | 6.7M |
| 2026-06-30 | Janku Filip | Chief Medical Officer | Sell | 5K | $24.50 | $132K | 61K |
| 2026-06-30 | Janku Filip | Chief Medical Officer | Exercise or conversion | 5K | $13.41 | $73K | 66K |
| 2026-06-29 | Manning Anthony M. | Director | Sell | 10K | $23.11 | $231K | 0 |
| 2026-06-29 | Manning Anthony M. | Director | Exercise or conversion | 10K | $4.16 | $42K | 10K |
| 2026-06-29 | Janku Filip | Chief Medical Officer | Sell | 6K | $22.95 | $138K | 60K |
| 2026-06-29 | Janku Filip | Chief Medical Officer | Exercise or conversion | 6K | $7.56 | $45K | 66K |
| 2026-06-24 | Janku Filip | Chief Medical Officer | Exercise or conversion | 30K | $7.56 | $227K | 90K |
| 2026-06-24 | Janku Filip | Chief Medical Officer | Sell | 30K | $21.42 | $643K | 60K |
| 2026-06-23 | Townson Sharon | Chief Scientific Officer | Sell | 3K | $20.00 | $60K | 68K |
| 2026-06-23 | Townson Sharon | Chief Scientific Officer | Exercise or conversion | 3K | $6.14 | $18K | 71K |
| 2026-06-23 | Janku Filip | Chief Medical Officer | Exercise or conversion | 6K | $7.56 | $45K | 72K |
| 2026-06-23 | Janku Filip | Chief Medical Officer | Sell | 12K | $20.22 | $240K | 60K |
| 2026-06-23 | Champoux Jennifer | Chief Operating Officer | Sell | 2K | $20.00 | $44K | 62K |
| 2026-06-23 | Champoux Jennifer | Chief Operating Officer | Exercise or conversion | 2K | $3.98 | $9K | 65K |
| 2026-06-17 | Townson Sharon | Chief Scientific Officer | Sell | 3K | $19.00 | $57K | 68K |
| 2026-06-17 | Townson Sharon | Chief Scientific Officer | Exercise or conversion | 3K | $6.14 | $18K | 71K |
| 2026-06-17 | Champoux Jennifer | Chief Operating Officer | Sell | 2K | $19.00 | $41K | 62K |
| 2026-06-17 | Champoux Jennifer | Chief Operating Officer | Exercise or conversion | 2K | $3.98 | $9K | 65K |
| 2026-06-01 | Warmuth Markus | President & CEO | Sell | 468 | $19.73 | $9K | 595K |
| 2026-06-01 | Warmuth Markus | President & CEO | Sell | 5K | $19.41 | $97K | 595K |
| 2026-05-29 | Townson Sharon | Chief Scientific Officer | Sell | 6K | $19.87 | $119K | 68K |
| 2026-05-29 | Townson Sharon | Chief Scientific Officer | Exercise or conversion | 6K | $6.14 | $37K | 74K |
| 2026-05-27 | Champoux Jennifer | Chief Operating Officer | Sell | 2K | $20.00 | $44K | 62K |
| 2026-05-27 | Champoux Jennifer | Chief Operating Officer | Exercise or conversion | 2K | $3.98 | $9K | 65K |
| 2026-05-22 | Champoux Jennifer | Chief Operating Officer | Sell | 2K | $19.00 | $41K | 62K |
| 2026-05-22 | Champoux Jennifer | Chief Operating Officer | Exercise or conversion | 2K | $3.98 | $9K | 65K |
| 2026-05-21 | Manning Anthony M. | Director | Sell | 10K | $18.01 | $180K | 0 |
| 2026-05-21 | Manning Anthony M. | Director | Exercise or conversion | 10K | $4.16 | $42K | 10K |
| 2026-05-01 | Warmuth Markus | President & CEO | Sell | 5K | $18.92 | $103K | 600K |
| 2026-04-14 | Warmuth Markus | President & CEO | Sell | 8K | $17.64 | $141K | 605K |
| 2026-04-09 | Nickson Philip | Chief Business & Legal Officer | Sell | 6K | $17.69 | $103K | 55K |
| 2026-04-06 | Bowen Matthew | Principal Accounting Officer | Grant | 4K | price not stated in the filing | not stated | 26K |
| 2026-03-04 | Dunn Edmund | Principal Accounting Officer | Sell | 139 | $17.96 | $2K | 23K |
| 2026-03-02 | Dunn Edmund | Principal Accounting Officer | Sell | 536 | $17.50 | $9K | 23K |
| 2026-03-02 | Dunn Edmund | Principal Accounting Officer | Exercise or conversion | 536 | $13.41 | $7K | 23K |
| 2026-03-02 | Warmuth Markus | President & CEO | Sell | 5K | $17.92 | $98K | 613K |
| 2026-02-27 | Dunn Edmund | Principal Accounting Officer | Sell | 25K | $18.10 | $456K | 23K |
| 2026-02-27 | Dunn Edmund | Principal Accounting Officer | Exercise or conversion | 25K | $13.41 | $337K | 48K |
| 2026-02-23 | Janku Filip | Chief Medical Officer | Sell | 9K | $19.50 | $179K | 66K |
| 2026-01-07 | Warmuth Markus | President & CEO | Sell | 309 | $24.57 | $8K | 619K |
| 2026-01-07 | Warmuth Markus | President & CEO | Sell | 1K | $23.88 | $35K | 619K |
| 2026-01-07 | Warmuth Markus | President & CEO | Sell | 4K | $23.24 | $86K | 621K |
| 2026-01-05 | Townson Sharon | Chief Scientific Officer | Sell | 3K | $15.17 | $48K | 68K |
| 2026-01-05 | Janku Filip | Chief Medical Officer | Sell | 3K | $15.17 | $48K | 75K |
| 2026-01-05 | Warmuth Markus | President & CEO | Sell | 10K | $15.17 | $154K | 624K |
| 2026-01-05 | Champoux Jennifer | Chief Operating Officer | Sell | 3K | $15.17 | $40K | 62K |
| 2026-01-05 | Nickson Philip | Chief Business & Legal Officer | Sell | 3K | $15.17 | $48K | 61K |
| 2026-01-05 | Dunn Edmund | Principal Accounting Officer | Sell | 1K | $15.17 | $16K | 23K |
| 2026-01-02 | Townson Sharon | Chief Scientific Officer | Grant | 35K | price not stated in the filing | not stated | 71K |
| 2026-01-02 | Janku Filip | Chief Medical Officer | Grant | 31K | price not stated in the filing | not stated | 78K |
| 2026-01-02 | Warmuth Markus | President & CEO | Grant | 90K | price not stated in the filing | not stated | 635K |
| 2026-01-02 | Champoux Jennifer | Chief Operating Officer | Grant | 35K | price not stated in the filing | not stated | 65K |
| 2026-01-02 | Nickson Philip | Chief Business & Legal Officer | Grant | 28K | price not stated in the filing | not stated | 64K |
| 2025-06-03 | Dunn Edmund | Principal Accounting Officer | Sell | 2K | $4.45 | $9K | 24K |
| 2025-03-24 | Leo Chandra P. | Director | Buy | 10K | $5.84 | $58K | 10K |
| 2025-01-02 | Townson Sharon | Chief Scientific Officer | Grant | 36K | price not stated in the filing | not stated | 36K |
| 2025-01-02 | Warmuth Markus | President & CEO | Grant | 128K | price not stated in the filing | not stated | 545K |
| 2025-01-02 | Champoux Jennifer | Chief Operating Officer | Grant | 30K | price not stated in the filing | not stated | 30K |
| 2025-01-02 | Janku Filip | Chief Medical Officer | Grant | 36K | price not stated in the filing | not stated | 45K |
| 2025-01-02 | Dunn Edmund | Principal Accounting Officer | Grant | 12K | price not stated in the filing | not stated | 26K |
| 2025-01-02 | Nickson Philip | Chief Business & Legal Officer | Grant | 36K | price not stated in the filing | not stated | 36K |
| 2024-10-29 | Versant Venture Capital VI, L.P. | TenPercentOwner | Sell | 52K | $9.08 | $475K | 1.6M |
| 2024-10-29 | Versant Venture Capital VI, L.P. | TenPercentOwner | Sell | 16K | $9.41 | $147K | 1.6M |
| 2024-10-28 | Versant Venture Capital VI, L.P. | 10% owner | Other transaction | 5K | $0.00 | $0 | 0 |
| 2024-10-28 | Versant Venture Capital VI, L.P. | 10% owner | Other transaction | 5K | $0.00 | $0 | 0 |
| 2024-10-28 | Versant Venture Capital VI, L.P. | 10% owner | Other transaction | 18K | $0.00 | $0 | 0 |
| 2024-10-28 | Versant Venture Capital VI, L.P. | 10% owner | Other transaction | 20K | $0.00 | $0 | 0 |
| 2024-10-28 | Versant Venture Capital VI, L.P. | TenPercentOwner | Other transaction | 367K | $0.00 | $0 | 1.6M |
| 2024-10-28 | Versant Venture Capital VI, L.P. | TenPercentOwner | Other transaction | 5K | $0.00 | $0 | 5K |
| 2024-10-28 | Versant Venture Capital VI, L.P. | TenPercentOwner | Other transaction | 5K | $0.00 | $0 | 5K |
| 2024-10-28 | Versant Venture Capital VI, L.P. | TenPercentOwner | Other transaction | 18K | $0.00 | $0 | 18K |
| 2024-10-28 | Versant Venture Capital VI, L.P. | TenPercentOwner | Other transaction | 20K | $0.00 | $0 | 20K |
| 2024-10-28 | Versant Venture Capital VI, L.P. | TenPercentOwner | Other transaction | 1.0M | $0.00 | $0 | 4.1M |
| 2024-10-28 | Versant Venture Capital VI, L.P. | TenPercentOwner | Sell | 90K | $9.66 | $869K | 2.0M |
| 2024-09-20 | Versant Venture Capital VI, L.P. | TenPercentOwner | Sell | 1.1M | $6.53 | $7.4M | 5.1M |
| 2024-09-13 | Versant Ventures VI GP, L.P. | TenPercentOwner | Sell | 9K | $6.16 | $57K | 6.2M |
| 2024-09-12 | Versant Ventures VI GP, L.P. | TenPercentOwner | Sell | 16K | $6.00 | $96K | 6.2M |
| 2024-09-11 | Versant Ventures VI GP, L.P. | TenPercentOwner | Sell | 542K | $6.00 | $3.3M | 6.3M |
| 2024-07-05 | Dunn Edmund | Principal Accounting Officer | Sell | 2K | $3.83 | $6K | 14K |
| 2024-06-03 | Dunn Edmund | Principal Accounting Officer | Sell | 1K | $4.04 | $5K | 16K |
| 2021-06-28 | Cormorant Asset Management, LP | Other | Buy | 600K | $19.00 | $11.4M | 3.2M |
| 2021-06-28 | Cormorant Asset Management, LP | Other | Conversion | 2.6M | price not stated in the filing | not stated | 2.6M |
| 2021-06-28 | Versant Ventures VI GP, L.P. | TenPercentOwner | Buy | 158K | $19.00 | $3.0M | 2.1M |
| 2021-06-28 | Versant Ventures VI GP, L.P. | TenPercentOwner | Conversion | 6.5M | price not stated in the filing | not stated | 6.8M |
| 2021-06-28 | Versant Ventures VI GP, L.P. | TenPercentOwner | Conversion | 1.9M | price not stated in the filing | not stated | 1.9M |
| 2021-06-28 | Bolzon Bradley J PhD | Director,TenPercentOwner | Conversion | 1.9M | price not stated in the filing | not stated | 1.9M |
| 2021-06-28 | Bolzon Bradley J PhD | Director,TenPercentOwner | Buy | 158K | $19.00 | $3.0M | 2.1M |
| 2021-06-28 | Bolzon Bradley J PhD | Director,TenPercentOwner | Conversion | 6.5M | price not stated in the filing | not stated | 6.8M |
| 2021-06-28 | NEA Partners 17, L.P. | TenPercentOwner | Buy | 1.1M | $19.00 | $19.9M | 7.7M |
| 2021-06-28 | NEA Partners 17, L.P. | TenPercentOwner | Conversion | 2.7M | price not stated in the filing | not stated | 2.7M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON30 Form 144 notices on file for GLUE worth $109.0M at the prices reported; 0 in the last 90 days worth $0. Latest: MARKUS WARMUTH filed on 2026-07-16 to sell 9,500 shares ($220K) from 2026-07-16.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-07-16 | MARKUS WARMUTHOfficer | 10K | $220K | 0.011% | 2026-07-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-15 | Champoux JenniferOfficer | 4K | $102K | 0.005% | 2026-07-15 | UBS Financial Services, Inc. |
| 2026-06-30 | FILIP JANKUOfficer | 5K | $129K | 0.006% | 2026-06-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-29 | ANTHONY M MANNINGDirector | 10K | $231K | 0.012% | 2026-06-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-29 | FILIP JANKUOfficer | 6K | $134K | 0.007% | 2026-06-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-24 | FILIP JANKUOfficer | 30K | $621K | 0.036% | 2026-06-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-23 | FILIP JANKUOfficer | 12K | $221K | 0.014% | 2026-06-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-23 | EDMUND DUNNOfficer | 17K | $345K | 0.020% | 2026-06-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-23 | Champoux JenniferOfficer | 2K | $40K | 0.003% | 2026-06-23 | UBS Financial Services, Inc. |
| 2026-06-17 | Champoux JenniferOfficer | 2K | $39K | 0.003% | 2026-06-17 | UBS Financial Services, Inc. |
| 2026-06-02 | Warmuth MarkusOfficer | 5K | $103K | 0.006% | 2026-05-01 | Rockefeller Capital Management |
| 2026-06-01 | Warmuth MarkusOfficer | 5K | $106K | 0.006% | 2026-06-01 | Rockefeller Capital Management |
| 2026-05-29 | SHARON TOWNSONOfficer | 24K | $465K | 0.028% | 2026-05-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-27 | Champoux JenniferOfficer | 2K | $42K | 0.003% | 2026-05-27 | UBS Financial Services, Inc. |
| 2026-05-22 | Champoux JenniferOfficer | 2K | $41K | 0.003% | 2026-05-22 | UBS Financial Services, Inc. |
| 2026-05-21 | ANTHONY M MANNINGDirector | 10K | $180K | 0.012% | 2026-05-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-01 | Warmuth MarkusOfficer | 5K | $103.4M | 0.006% | 2026-05-01 | Rockefeller Capital Management |
| 2026-04-16 | EDMUND DUNNOfficer | 19K | $346K | 0.023% | 2026-04-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-14 | MARKUS WARMUTHOfficer, Director | 8K | $141K | 0.010% | 2026-04-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-13 | EDMUND DUNNOfficer | 17K | $300K | 0.021% | 2026-04-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-09 | PHILIP NICKSONOfficer | 6K | $103K | 0.007% | 2026-04-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-08 | EDMUND DUNNOfficer | 26K | $451K | 0.033% | 2026-04-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-04 | Dunn EdmundOfficer | 139 | $2K | 0.000% | 2026-03-04 | Morgan Stanley Smith Barney LLC |
| 2026-03-02 | Warmuth MarkusOfficer | 5K | $98K | 0.007% | 2026-03-02 | Rockefeller Capital Management |
| 2026-03-02 | Edmund DunnOfficer | 536 | $9K | 0.001% | 2026-03-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-27 | Edmund DunnOfficer | 25K | $456K | 0.039% | 2026-02-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-23 | FILIP JANKUOfficer | 9K | $179K | 0.014% | 2026-02-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-08 | Warmuth MarkusOfficer | 5K | $128K | 0.008% | 2026-01-07 | Rockefeller Capital Management |
| 2026-01-07 | Warmuth MarkusOfficer | 5K | $128K | 0.008% | 2026-01-07 | Rockefeller Capital Management |
| 2026-01-05 | Warmuth MarkusOfficer, Director | 10K | $154K | 0.015% | 2026-01-05 | Morgan Stanley Smith Barney LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first, 50 of 55 shown. JSON25 holders report 5% or more of GLUE in their latest filing, 6 on Schedule 13D (active intent). The largest reported stake is T. Rowe Price Associates, Inc. at 10.5% of the class (8,861,282 shares), filed 2026-07-08 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 1 | Montanova Capital, LLCinvestment adviser, other entity | 3.5M | 4.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Aaron Cowenparent holding company, individual | 3.5M | 4.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Averill Master Fund, Ltd.corporation | 3.2M | 3.8% | 2026-06-30 |
| 2026-08-14 | 13G | Vestal Point Capital, LPinvestment adviser, partnership | 4.6M | 5.4% | 2026-06-30 |
| 2026-08-14 | 13G | Ryan Wilderparent holding company, individual | 4.6M | 5.4% | 2026-06-30 |
| 2026-07-08 | 13G/Ano. 7 | T. Rowe Price Associates, Inc.investment adviser | 8.9M | 10.5% | 2026-06-30 |
| 2026-07-06 | 13D/Ano. 4 | New Enterprise Associates 17, L.P.partnership | 6.7M | 7.9% | 2026-07-01 |
| 2026-07-06 | 13D/Ano. 4 | Scott D. Sandellindividual | 6.7M | 7.9% | 2026-07-01 |
| 2026-07-06 | 13D/Ano. 4 | Mohamad H. Makhzoumiindividual | 6.7M | 7.9% | 2026-07-01 |
| 2026-07-06 | 13D/Ano. 4 | Anthony A. Florence, Jr.individual | 6.7M | 7.9% | 2026-07-01 |
| 2026-07-06 | 13D/Ano. 4 | NEA 17 GP, LLCother entity | 6.7M | 7.9% | 2026-07-01 |
| 2026-07-06 | 13D/Ano. 4 | NEA Partners 17, L.P.partnership | 6.7M | 7.9% | 2026-07-01 |
| 2026-07-06 | 13D/Ano. 4 | Ali Behbahaniindividual | 135K | 0.2% | 2026-07-01 |
| 2026-07-06 | 13D/Ano. 4 | Rick Yangindividual | 0 | 0.0% | 2026-07-01 |
| 2026-07-06 | 13D/Ano. 4 | Paul Walkerindividual | 0 | 0.0% | 2026-07-01 |
| 2026-07-06 | 13D/Ano. 4 | Edward T. Mathersindividual | 0 | 0.0% | 2026-07-01 |
| 2026-07-06 | 13D/Ano. 4 | Carmen Changindividual | 0 | 0.0% | 2026-07-01 |
| 2026-07-06 | 13D/Ano. 4 | Forest Baskettindividual | 0 | 0.0% | 2026-07-01 |
| 2026-05-15 | 13G/Ano. 1 | Chen Yuindividual | 4.6M | 5.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | TCG Crossover GP II, LLCother entity | 2.3M | 2.7% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | TCG Crossover Fund III, L.P.partnership | 2.3M | 2.7% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | TCG Crossover GP III, LLCother entity | 2.3M | 2.7% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | TCG Crossover Fund II, L.P.partnership | 2.3M | 2.7% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Baker Bros. Advisors (GP) LLCparent holding company, other entity | 8.9M | 10.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Felix J. Bakerparent holding company, individual | 8.9M | 10.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Baker Bros. Advisors LPinvestment adviser, partnership | 8.9M | 10.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Julian C. Bakerparent holding company, individual | 8.9M | 10.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 3 | BVF PARTNERS L P/ILinvestment adviser, partnership | 5.1M | 6.3% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 3 | LAMPERT MARK Nindividual | 5.1M | 6.3% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 3 | BVF INC/ILcorporation | 5.1M | 6.3% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 3 | BVF GP HOLDINGS LLCother entity | 4.7M | 5.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 3 | BVF I GP LLCother entity | 2.7M | 3.4% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 3 | BIOTECHNOLOGY VALUE FUND L Ppartnership | 2.7M | 3.4% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 3 | BVF II GP LLCother entity | 2.0M | 2.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 3 | BIOTECHNOLOGY VALUE FUND II LPpartnership | 2.0M | 2.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 3 | BVF Partners OS Ltd.corporation | 306K | 0.4% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 3 | Biotechnology Value Trading Fund OS LPpartnership | 306K | 0.4% | 2026-03-31 |
| 2026-04-22 | 13G/Ano. 2 | Nan Liindividual | 6.5M | 8.1% | 2026-03-31 |
| 2026-04-22 | 13G/Ano. 2 | Dimension Management, L.P.investment adviser | 6.5M | 8.1% | 2026-03-31 |
| 2026-04-22 | 13G/Ano. 2 | Dimension Management GP, LLCcorporation | 6.5M | 8.1% | 2026-03-31 |
| 2026-04-22 | 13G/Ano. 2 | Adam Goulburnindividual | 6.5M | 8.1% | 2026-03-31 |
| 2026-04-22 | 13G/Ano. 2 | Zavain Darindividual | 6.5M | 8.1% | 2026-03-31 |
| 2026-04-22 | 13G/Ano. 2 | Dimension Capital I GP, LLCcorporation | 5.7M | 7.1% | 2026-03-31 |
| 2026-04-22 | 13G/Ano. 2 | Dimension Capital I, L.P.partnership | 5.7M | 7.1% | 2026-03-31 |
| 2026-04-22 | 13G/Ano. 2 | Dimension Capital II GP, LLCcorporation | 851K | 1.1% | 2026-03-31 |
| 2026-04-22 | 13G/Ano. 2 | Dimension Capital II, L.P.partnership | 851K | 1.1% | 2026-03-31 |
| 2026-01-09 | 13D/Ano. 6 | Versant Ventures VI GP-GP, LLCother entity | 2.2M | 3.4% | 2026-01-07 |
| 2026-01-09 | 13D/Ano. 6 | Versant Venture Capital VI, L.P.partnership | 2.2M | 3.4% | 2026-01-07 |
| 2026-01-09 | 13D/Ano. 6 | Versant Ventures VI GP, L.P.partnership | 2.2M | 3.4% | 2026-01-07 |
| 2026-01-09 | 13D/Ano. 6 | Versant Vantage I GP-GP, LLCother entity | 1.0M | 1.6% | 2026-01-07 |
13F holders
Tracked managers holding GLUE at their latest 13F. JSON7 of the 30 tracked managers held GLUE at their latest 13F, $42.6M in total at quarter-end prices. AQR Capital Management is the largest at $12.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 521K | $12.6M | 0.00% | -138K |
| Fisher Asset Management | 2026-06-30 | 364K | $8.8M | 0.00% | +49K |
| Duquesne Family Office | 2026-06-30 | 298K | $7.2M | 0.14% | new |
| D. E. Shaw & Co. | 2026-06-30 | 172K | $4.2M | 0.00% | +106K |
| Citadel Advisors | 2026-06-30 | 164K | $4.0M | 0.00% | -91K |
| Two Sigma Investments | 2026-06-30 | 141K | $3.4M | 0.00% | +122K |
| Renaissance Technologies | 2026-06-30 | 103K | $2.5M | 0.00% | -277K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Monte Rosa Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Monte Rosa Therapeutics (GLUE), SEC CIK 1826457, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-02.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-07-16.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-05.JSON and CSV
- Company record
- EDGAR filing index for CIK 1826457Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of GLUE is sold short?
20,660,257 shares were held short at the 2026-10-15 settlement, 11.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is GLUE's daily short volume?
On 2026-11-02, 330,544 of the 476,211 GLUE shares reported to FINRA were sold short, 69.4% of the day's reported volume. Short volume is a flow for one day, not a position.
Does GLUE have fails to deliver?
The SEC's latest file shows 3 GLUE shares failed to deliver at settlement 2026-10-02. Fails are reported per settlement date and published twice a month with a lag.
Are GLUE insiders buying or selling?
Insiders at GLUE reported 1 open-market sell worth $137 in the last 90 days and no open-market buys. Latest filing: Bowen Matthew (Principal Accounting Officer) on 2026-10-05.
Have GLUE insiders filed to sell?
30 Form 144 notices on file for GLUE worth $109.0M at the prices reported; 0 in the last 90 days worth $0. Latest: MARKUS WARMUTH filed on 2026-07-16 to sell 9,500 shares ($220K) from 2026-07-16.
Who owns 5% or more of GLUE?
25 holders report 5% or more of GLUE in their latest filing, 6 on Schedule 13D (active intent). The largest reported stake is T. Rowe Price Associates, Inc. at 10.5% of the class (8,861,282 shares), filed 2026-07-08 for an event on 2026-06-30.
Which tracked 13F managers own GLUE?
7 of the 30 tracked 13F managers held GLUE shares at their latest filing, $42.6M in all. The largest: Cliff Asness's AQR Capital Management (521K shares, $12.6M), Ken Fisher's Fisher Asset Management (364K shares, $8.8M), Stanley Druckenmiller's Duquesne Family Office (298K shares, $7.2M), D. E. Shaw & Co. (172K shares, $4.2M), Ken Griffin's Citadel Advisors (164K shares, $4.0M), Two Sigma Investments (141K shares, $3.4M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.